Regenxbio was founded in 2009 and is headquartered in Rockville, US
Report incorrect company information
Key People/Management at Regenxbio
Ken Mills
President and Chief Executive Officer
Vit Vasista
CFO
Stephen Yoo
Chief Medical Officer
Olivier Danos
Chief Scientific Officer
Curran Simpson
Senior Vice President, Technical Operations
Kimberly Sloan
Senior Vice President, Human Resources
Report incorrect company information
Regenxbio Office Locations
Regenxbio has an office in Rockville
Rockville, US (HQ)
100 9712 Medical Center Dr
Report incorrect company information
Regenxbio Financials and Metrics
Regenxbio Financials
Regenxbio's revenue was reported to be $10.39 m in FY, 2017
| USD | |
|---|---|
Revenue (Q1, 2018) | 132.4 m |
Net income (Q1, 2018) | 104.2 m |
EBIT (Q1, 2018) | 102 m |
Market capitalization (14-Jun-2018) | 1.8 b |
Closing share price (14-Jun-2018) | 56 |
Cash (31-Mar-2018) | 71.9 m |
Regenxbio's current market capitalization is $1.8 b.
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.1 x |
Report incorrect company information
Regenxbio News and Updates
June 05, 2018
Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR
This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…
December 21, 2017
Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023
This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information